Answers are grounded in this paper and cite their sources.
Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. December 19, 2017 ARTICLE CITATION DOI: 10.1200/JCO.2017.77.5254 Journal of Clinical Oncology - published online before print January 31, 2018 PMID: 29384723 HIF2 Inhibitor Joins the Kidney Cancer Armamentarium William G. Kaelin JrxWilliam G. Kaelin JrSearch for articles by this author Show More William G. Kaelin Jr, Harvard Medical School, Boston, MA https://doi.org/10.1200/JCO.2017.77.5254 First Page Full Text PDF Figures and Tables © 2018 by American Society of Clinical Oncology Companion Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
No takes yet. Share an insight, caveat, or question.
William G. Kaelin (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: